Our Research
Advancing complement biology for ocular disease
Complement Therapeutics’ research is focused on understanding the role of the complement system in sight-threatening ocular conditions. By interrogating disease-relevant pathways at a mechanistic level, our research aims to identify precise points of intervention with the potential to modify disease progression.
Our approach is grounded in human biology, translational relevance, and clinical applicability, ensuring that research outputs meaningfully inform downstream development decisions.
From discovery to translation
Research activities at Complement are designed to bridge discovery and development. Experimental models, biomarker strategies, and disease-relevant systems are selected to support translational confidence and regulatory alignment.
This focus enables early assessment of clinical relevance and supports a disciplined progression from hypothesis generation through to development-ready programmes.
Discovery
Translation
Development
A collaborative research environment
Complement Therapeutics operates across three leading life science hubs in Europe, supporting close collaboration between research, translation, and development.
Research activities are carried out across Munich, the White City Campus of Imperial College London, and Stevenage Bioscience Catalyst, providing access to complementary academic, clinical, and industry expertise. This multi-site presence enables rigorous research execution and supports access to specialist capabilities across the translational pathway.
Explore our research and development programmes or contact the team regarding scientific collaboration, partnerships, or general enquiries.
